Important notice regarding Rhopressa

Posted in Latest News on February 12, 2019.

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa.



More Latest News

First Quarter Performance Report
November 30, 2021

Released for the
2021 – 2022 Fiscal Year Continue reading


The Annual Report and Long-Range Plan Released for Fiscal Year 2020-21
November 1, 2021

The Annual Report and Long-Range Plan for Fiscal Year 2020-21
is now online. Continue reading